· Laquinimod ― Teva extends its marketing and distribution rights for
laquinimod
· TASQ ― preparations for Phase III trials under way
· ANYARA ― exploratory combination data presented
· 57-57 ― exploratory clinical trial in progress
· ISI ― project proceeding according to plan
· RhuDex((TM) )― preclinical studies in progress
· Net sales of SEK 2.8 M (2.2)
· Operating loss of SEK 51.0 M (loss: 63.7)
· Loss after tax of SEK 53.5 M (loss: 62.2)
· Loss per share for the period amounted to SEK 0.83 (loss: 1.21)
· After the end of the period a directed share issue raised
approximately SEK 149 M for the company
For further information, please contact:
Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95
Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54
Hans
Kolam
CFO
Tel: +46 (0)46-19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
This report is also available at www.activebiotech.com
<http://www.activebiotech.com/>
[HUG#1406538]
